---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-125940"
form_type: "8-K"
ticker: "LXEO"
cik: "0001907108"
company_name: "Lexeo Therapeutics, Inc."
filed_at: "2024-11-13T23:59:59+00:00"
generated_at: "2026-05-30T01:16:18.422118+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Lexeo reaches FDA alignment on accelerated approval for LX2006; Q3 net loss $29.5M, cash $157M

## Summary
- FDA agreed on co-primary registrational endpoints (LVMI reduction and frataxin expression) for LX2006 accelerated approval.
- Received RMAT designation for LX2006; completed enrollment in SUNRISE-FA Phase 1/2 (16 patients dosed to date).
- LX2020 PKP2-ACM cohort 1 enrollment completed; initial safety/biodistribution data expected late Q1/Q2 2025.
- Q3 net loss $29.5M ($0.89 per share) vs $20.1M year-ago; R&D $23.4M, G&A $8.1M.
- Cash $157M expected into 2027; Tolga Tanguler (Alnylam exec) appointed to board.

## SEC filing metadata
- accession: 0000950170-24-125940
- form_type: 8-K
- ticker: LXEO
- cik: 0001907108
- company_name: Lexeo Therapeutics, Inc.
- filed_at: 2024-11-13T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1907108/000095017024125940/0000950170-24-125940-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1907108/000095017024125940/lxeo-20241111.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-125940
- JSON: https://secwatch.observer/filing/0000950170-24-125940.json
- Plain text: https://secwatch.observer/filing/0000950170-24-125940.txt

## Key facts
- Executive change
  Tolga Tanguler was appointed as director at Lexeo Therapeutics, Inc..
  - Action: appointed
  - Role: director
  source text: On November 11, 2024 (the “ Appointment Date ”), Tolga Tanguler was appointed to the board of directors of the Company (the “ Board ”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1907108/000095017024125940/0000950170-24-125940-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.